Understanding how inflammation affects the immune environment in tumors
Investigating the Genesis of Tumor Immune Microenvironment (TIME) as a function of Inflammation
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11210737
This study is looking at how inflammation affects the immune system in breast cancer, especially in tumors that don’t have T cells, to find ways to boost the body’s ability to fight the cancer and improve treatment outcomes, including the potential benefits of using aspirin.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11210737 on ClinicalTrials.gov |
What this research studies
This research investigates how inflammation influences the immune microenvironment in breast cancer, particularly focusing on tumors that lack T cells, known as 'cold' tumors. The study aims to identify the biological factors that lead to these immunosuppressive environments, using a model that mimics the effects of radiation therapy. By examining the role of systemic inflammation and treatments like aspirin, the research seeks to uncover potential strategies to enhance anti-tumor immunity and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include breast cancer patients, especially those with cold tumors or those who have undergone radiation therapy.
Not a fit: Patients with tumors that are already responsive to immunotherapy or those without breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against breast cancer, particularly for patients with cold tumors.
How similar studies have performed: Previous research has shown promising results in understanding tumor immune microenvironments and the role of inflammation, suggesting that this approach could yield valuable insights.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BARCELLOS-HOFF, MARY HELEN — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: BARCELLOS-HOFF, MARY HELEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy